Ledu Y. Zhou

110 Xiangya Road
Changsha, 410078, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy.

Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy.

Journal: Cell reports. Medicine

Published: November 09, 2025

USP2-mediated PPARγ stabilization promotes hepatocellular carcinoma progression and M2 macrophage polarization via oleic acid.

USP2-mediated PPARγ stabilization promotes hepatocellular carcinoma progression and M2 macrophage polarization via oleic acid.

Journal: Journal for immunotherapy of cancer

Published: October 16, 2025

The impact of proximity to major central hepatic vasculature on perioperative outcomes and size-based risk stratification in hepatic hemangioma surgery.

The impact of proximity to major central hepatic vasculature on perioperative outcomes and size-based risk stratification in hepatic hemangioma surgery.

Journal: PloS one

Published: May 15, 2025

Deubiquitylating Enzymes in Hepatocellular Carcinoma.

Deubiquitylating Enzymes in Hepatocellular Carcinoma.

Journal: International journal of biological sciences

Published: March 04, 2025

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Journal: Hepatobiliary surgery and nutrition

Published: February 28, 2025

Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.

Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: November 13, 2024

China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).

China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).

Journal: Liver cancer

Published: November 04, 2024

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.

Journal: Liver cancer

Published: October 12, 2024

Analysis of problems and management of in vitro diagnostic reagent clinical trials in medical laboratory

Analysis of problems and management of in vitro diagnostic reagent clinical trials in medical laboratory

Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Published: September 18, 2024

Postoperative recurrent jaundice and fever: A deceptive case caused by hemobilia.

Postoperative recurrent jaundice and fever: A deceptive case caused by hemobilia.

Journal: International journal of surgery case reports

Published: March 27, 2024

Antimicrobials discovery against Staphylococcus aureus by high throughput screening of drug library

Antimicrobials discovery against Staphylococcus aureus by high throughput screening of drug library

Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Published: November 26, 2023

USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT.

USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT.

Journal: Cancer cell international

Published: October 12, 2023

Showing 1-12 of 51

Last Updated: 09/26/2026